Strategy feasibility of darbepoetin alfa administration every other week: 2005-2007 experience in a dialysis unit;Faisabilitéde la stratégie d'administration de la darbepoetin alfa tous les 15 jours : expérience 2005-2007 d'un centre de dialyse

Nephrologie et Therapeutique

Volumn 7, Issue 7, 2011, Pages 549-557

  Rottembourg, Jacques B ^a   Dansaert, Aurélie ^a  

^a Centre Suzanne Levy   (France)

Author keywords

Anaemia; Darbepoetin alfa; Haemodialysis; Haemoglobin

Indexed keywords

HEMOGLOBIN; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; ANTIANEMIC AGENT; DRUG DERIVATIVE; ERYTHROPOIETIN;

ANEMIA; ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; DIABETIC PATIENT; DIALYSIS; DRUG RESPONSE; HEMOGLOBIN BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; NURSE; TIME; ADULT; AGED; BLOOD; CHRONIC KIDNEY FAILURE; DRUG ADMINISTRATION; FEASIBILITY STUDY; FEMALE; HEMODIALYSIS; INTRAVENOUS DRUG ADMINISTRATION; MALE; METABOLISM; MIDDLE AGED; RENAL REPLACEMENT THERAPY; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANEMIA; DRUG ADMINISTRATION SCHEDULE; ERYTHROPOIETIN; FEASIBILITY STUDIES; FEMALE; HEMATINICS; HEMODIALYSIS UNITS, HOSPITAL; HEMOGLOBINS; HUMANS; INJECTIONS, INTRAVENOUS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; RENAL DIALYSIS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84861427680     PISSN: 17697255     EISSN: 18729177     Source Type: Journal    
DOI: 10.1016/j.nephro.2011.03.011     Document Type: Article

References (69)

1. Eschbach JW, Egrie JC, Downing MR, et al. Correction of the anemia of endstage renal disease with recombinant human erythropoietin. Results of a combined phase I and II clinical trial. N Engl J Med 1987;316:73-8.
2. Traitement de l'ane'mie au cours de l'insuffisance ré nale chronique de l'adulte; recommandations de l'Afssaps. Nephrol Ther 2005;1(Suppl. 1):S1-48.
3. National Kidney Foundation: NKF-DOQI clinical practice guidelines for the treatment of anemia of chronic renal failure. Am J Kidney Dis 1997;30(Suppl. 3):S192-230.
4. National Kidney Foundation: NKF-K/DOQI clinical practice guidelines for anemia of chronic kidney diseases: Update 2000. Am J Kidney Dis 2001;37(Suppl. 1):S182-238.
5. Locatelli F, Aljama P, Barany P, et al. Revised European best practice guidelines for the management of anaemia in patients with chronic renal failure. Nephrol Dial Transplant 2004;19(Suppl. 2):ii1-47.
6. KDOQI. Clinical practice guidelines and clinical practice recommendations for anemia in chronic kidney disease. Am J Kidney Dis 2006;47:S11-47.
7. Drueke T, Locatelli F, Clyne N, et al. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. New Engl J Med 2006;355:2071-84.
8. Singh A, Saczech L, Tang KL, et al. Correction of anemia with epoietin alfa in chronic kidney disease. New Eng J Med 2006;355:2085-98.
9. Pfeffer MA, Burdmann EA, Chen CY, et al. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. New Eng J Med 2009;361:2019-32.
10. KDOQI. Clinical practice guideline and clinical practice recommendations for anemia in chronic kidney disease - 2007 update of haemoglobin target. Am J Kidney Dis 2007;50:471-530.
11. Macdougall IC, Eckardt KU, Locatelli F. Latest US KDOQI anemia guidelines update - what are the implications for Europe? Nephrol Dial Transplant 2007;22:2738-42.
12. US Food and Drug Administration Information for Healthcare, Center for Drug Evaluation and Research. Public Health Advisory. Available at http://www.fda.gov/cder/drug/InfoSheets/HCP/RHE2007HCP.
13. Locatelli F, Aljama P, Canaud B, Covic A, et al. Target haemoglobin to aim for with erythropoiesis-stimulating agents: A position statement by ERBP following publication of the Trial to Reduce Cardiovascular Events with Aranesp1 Therapy (TREAT) Study. Nephrol Dial Transplant 2010;25:2846-50.
14. Besarab A, Reyes CM, Horneger J. Meta-Analysis of subcutaneous versus intravenous epoetin in maintenance treatment of anemia in hemodialysis patients. Am J Kidney Dis 2002;40:439-46.
15. Casedewall N, Nataf J, Viron B, Kolta A, et al. Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin. N Eng J Med 2002;346:469-75.
16. Macdougall IC, Padhi D, Jang G. Pharmacology of darbepoetin. Nephrol Dial Transplant 2007;22(Suppl. 4):2-9.
17. Cervelli MJ, Gray N, MacDonald S, Gentgall MG, Disney APS. Randomized cross over comparison of intravenous and subcutaneous darbepoetin dosing efficiency in haemodialysis patients. Nephrology 2005;10:129-35.
18. Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation. J Chronic Dis 1987;40:373-83.
19. Eckardt KU, Kim J, Kronenberg F, Aljama P, Anker SD, et al. Hemoglobin variability does not predict mortality in european hemodialysis patients. J Am Soc Nephrol 2010;21:1765-75.
20. Bock A. Conversion from weekly epoetin to bi-weekly darbepoetin alfa maintains haemoglobin and permits dose reductions at higher doses: Results from a prospective study. Nephrol Dial Transplant 2005;20:v261.
21. Locatelli F, Canaud B, Giacardy F, Martin-Malo A, Baker N, Wilson J. Treatment of anaemia in dialysis patients with unit dosing of darbepoetin alfa at a reduced dose frequency relative to recombinant human erythropoietin (rHuEpo). Nephrol Dial Transplant 2003;18:362-9.
22. Brunkhorst R, Bommer J, Braun J, Haag-Weber M, Gill C, Wagner J, et al. Darbepoetin alfa effectively maintains haemoglobin concentrations at extended dose intervals relative to intravenous or subcutaneous recombinant human erythropoietin in dialysis patients. Nephrol Dial Transplant 2004;19:1224-30.
23. Mann JF, Kessler M, Villa G, Martinez-Castelao A, Feldt-Rasmussen B, Cruz J, et al. Darbepoetin alfa once every 2 weeks for treatment of anemia in dialysis patients: A combined analysis of eight multicenter trials. Clin Nephrol 2007;67:140-8.
24. Carrera F, Oliveira L, Maia P, Mendes T, Ferreira C. The efficacy of intravenous darbepoetin alfa administered once every 2 weeks in chronic kidney disease patients on haemodialysis. Nephrol Dial Transplant 2006;21:2846-50.
25. Carrera F, Disney A, Molina M. Extended dosing intervals with erythropoiesisstimulating agents in chronic kidney diseases: A review of clinical datas. Nephrol Dial Transplant 2007;22(Suppl. 4):19-30.
26. Besarab A, Frinak S, Yee J. What is so bad about a hemoglobin level of 12 to 13 g/dL for chronic kidney disease patients anyway? Adv Chronic Kidney Dis 2009;16(2):131-42.
27. Fishbane S, Berns JS. Hemoglobin cycling in hemodialysis patients treated with recombinant human erythropoietin. Kidney Int 2005;68:1337-43.
28. Kessler M, Landais P, Canivet E, Yver L, Bataille P, et al. La prise en charge de l'ane'mie du patient he'modialysé en France s'amé liore-T-elle ? Ré sultats de l'e'tude DiaNE. Nephrol Ther 2009;5:114-21.
29. Mann JF, de Francisco A, Nassar G, Beyer U. Fewer dose changes with oncemonthly CERA than with other erythropoiesis-stimulating agents (ESAs) in patients with chronic kidney disease (CKD): A pooled analysis of four studies. Nephrol Dial Transplant 2008;23:B152.
30. Patterson P, Allon M. Prospective evaluation of an anemia treatment algorithm in hemodialysis patients. Am J Kidney Dis 1998;32:635-41.
31. Brier ME, Gaweda AE, Dailey A, Aronoff GR, Jacobs AA. Randomized Trial of model predictive control for improved anemia management. Clin J Am Soc Nephrol 2010;5:814-20.
32. Spiegel DM, Gitlin M, Mayne T. Factors affecting anemia management in hemodialysis patients: A single-center experience. Hemodialysis Int 2008;12:336-41.
33. Di Lorio BR, Stellato D, De Santo N, Cirillo M. Association of gender and age with erythropoietin resistance in hemodialysis patients: Role of menstrual status. Blood Purif 2004;22:423-7.
34. Lacson Jr E, Rogus J, Teng M, Lazarus JM, Hakim RM. The association of race with erythropoietin dose in patients on long-Term hemodialysis. Am J Kidney Dis 2008;52:1104-14.
35. Powers JS, Krantz SB, Collins JC, Meurer K, Failinger A, Buchholz T, et al. Erythropoietin response to anemia as a function of age. J Am Geriatr Soc 1991;39:30-2.
36. Novak JE, Szczech LA. Triumph and tragedy: Anemia management in chronic kidney disease. Curr Opin Nephrol Hypert 2008;17:580-8.
37. Collins AJ, Ebben JP, Gilbertson DT. EPO adjustments in patients with elevated hemoglobin levels: Provider practice patterns compared with recommended practice guidelines. Am J Kidney Dis 2006;49:135-42.
38. Eben JP, Gilbertson DT, Foley RN, Collins AJ. Hemoglobin level variability: Associations with comorbidity, intercurrent events, and hospitalizations. Clin J Am Soc Nephrol 2006;1:1205-10.
39. Johnson DW, Pollock CA, Macdougall IC. Erythropoiesis-stimulating agent hyporesponsiveness. Nephrology 2007;12:321-30.
40. Lopez-Gomez JM, Perez-Flores I, Jofre R, et al. Presence of a failed kidney transplant in patients who are on hemodialysis is associated with chronic inflammatory state and erythropoietin resistance. J Am Soc Nephrol 2004;15:2494-501.
41. Lacson Jr E, Ofsthun N, Lazarus JM. Effect of variability in anemia management on haemoglobin outcomes in ESRD. Am J Kidney Dis 2003;41:111-24.
42. Adamson JW. Hyporesponsiveness to erythropoiesis stimulating agents in chronic kidney disease: The many faces of inflammation. Adv Chronic Kidney Dis 2009;16(2):76-82.
43. Elliott J, Mishler D, Agarwal R. Hyporesponsiveness to erythropoietin: Causes and management. Adv Chronic Kidney Dis 2009;16(2):94-100.
44. Ishani A, Solid CA, WeinhandlED, Gilbertson DT, Foley RN. Association between number of months below K/DOQI haemoglobin target and risk of hospitalization and death. Nephrol Dial Transplant 2008;23:1682-9.
45. Fishbane S, Berns JS. Evidence and implications of haemoglobin cycling in anaemia management. Nephrol Dial Transplant 2007;22:2129-32.
46. Rossert J, Gassman-Mayer C, Frei D, McClellan W. Prevalence and predictors of epoetin hyporesponsiveness in chronic kidney disease patients. Nephrol Dial Transplant 2007;22:794-800.
47. Al Khoury S, Afsli B, Shah N, Covic C, Thomas S, Goldsmith DJ. Anemia in diabetic patients with chronic kidney disease - prevalence and predictors. Diabetologia 2006;49:1183-9.
48. Mohanram A, Zhang Z, Shahinfar S, Keane WF, Brenner BM, Toto RD. Anemia and end stage renal disease in patients with type 2 diabetes and nephropathy. Kidney Int 2004;66:1131-8.
49. Ritz E, Laville M, Bilous RW, O'Donoghue D, Scherhag A, Burger U, et al. Target level for hemoglobin correction in patients with diabetes and CKD: Primary results of the Anemia Correction in Diabetes (ACORD) Study. Am J Kidney Dis 2007;49:194-207.
50. Thomas MC, Cooper ME, Tsalamandris C, Mac Isaac R, Jerums G. Anemia with impaired erythropoietin response in diabetic patients. Arch Intern Med 2005;165:466-9.
51. Li Vecchi M, Fuiano G, Francesco M, et al. Prevalence and severity of anaemia in patients with type 2 diabetic nephropathy and different degrees of chronic renal insufficiency. Nephron Clin Pract 2007;105:c62-7.
52. Gilbertson DT, Ebben JP, Foley RN, Weinhandl ED, Bradbury BD, Collins AJ. Hemoglobin level variability: Associations with mortality. Clin J Am Soc Nephrol 2008;3:133-8.
53. Ma JZ, Ebben JP, Xia H, et al. Hematocrit level and associated mortality in hemodialysis patients. J Am Soc Nephrol 1999;10:610-9.
54. Xia H, Ebben JP, Ma JZ, Collins AJ. Hematocrit levels and hospitalization risks in hemodialysis patients. J Am Soc Nephrol 1999;10:1309-16.
55. Brunelli SM, Joffe MM, Israni RK, Yang W, Fishbane S, Berns JS, et al. Historyadjusted marginal structural analysis of the association between haemoglobin variability and mortality among chronic hemodialysis patients. Clin J Am Soc Nephrol 2008;3:777-82.
56. Ishani A, Solid CA, Weinhandl ED, Gilbertson DT, Foley RN, Collins AJ. Associations between number of months below K/DOQI haemoglobin target and risk of hospitlization and death. Nephrol Dial Transplant 2008;23: 1682-9.
57. De Francisco ALM, Macdougall IC, Carrera F, Braun J, Barany P. Intercurrents events and comorbid conditions influence haemoglobin level variability in dialysis patients. Clin Nephrol 2009;71:397-404.
58. Foley RN, Parfrey PS, Harnett JD, Kent GM, Murray DC, Barre PE. The impact of anemia on cardiomyopathy, morbidity, and mortality in end stage renal disease. Am J Kidney Dis 1996;28:53-61.
59. Hertel J, Locay H, Scarlata D, Jackson L, Prathikanti R, Audhya P. Darbepoetin alfa administered every other week maintains hemoglobin levels over 52 weeks in patients with chronic kidney disease converting from onceweekly recombinant human erythropoietin: Results from simplify the treatment of anemia with Aranesp (STAAR). Am J Nephrol 2006;26:149-56.
60. Burnier M, Demay J, Tanghe A, Douchamps J. Improving anemia management with less frequently dosed erythropoiesis stimulating agents. Nephrol Dial Transplant 2007;22(Suppl. 6):199-200.
61. Besarab A, Amin N, Ashan M, et al. Optimization of epoetin therapy with intravenous iron therapy in hemodialysis patients. J Am Soc Nephrol 2000;11:530-8.
62. Coyne DW, Kapoian T, Suki W, et al. Ferric gluconate is highly efficacious in anemic hemodialysis patients with high serum ferritin and low transferrin saturation: Results of the dialysis patients' response to IV iron with elevated ferritin (DRIVE) Study. J Am Soc Nephrol 2007;18:975-84.
63. Kalantar-Zadeh K, Regidor DL, McAllister CJ, Michael B, Warnock DG. Time dependent associations between iron and mortality in hemodialysis patients. J Am Soc Nephrol 2005;16:3070-80.
64. Singh A. Hemoglobin control, ESA resistance, and regular low dose IV iron therapy: A review of evidence. Semin Dial 2008;21:1-6.
65. Kwack C, Balakrisnan VS. Managing erythropoietin hyporesponsiveness. Semin Dial 2006;19:146-51.
66. Priyadarshi A, Shapiro JI. Erythropoietin resistance in the treatment of the anemia of chronic renal failure. Semin Dial 2006;19:273-8.
67. Yee J, Zasuwa G, Frinak S, Besarab A. Hemoglobin variability and hyporesponsiveness: Much ado about something or nothing. Adv Chronic Kidney Dis 2009;16:83-93.
68. Kalentar-Zadeh K, Lee GH, Miller JE, Streja E, Jing J, Robertson JA, et al. Predictors of hyporesponsiveness to erythropiesis-stimulating agents in hemodialysis patients. J Am Soc Nephrol 2009;53:823-34.
69. Kainz A, Mayer B, Kramar R, Oberbauer R. Association of ESA hypo-responsiveness and haemoglobin variability with mortality in haemodialysis patients. Nephrol Dial Transplant 2010;25:3701-6.